This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutAboutExtended CoveragePK and PD ProfileGood Safety ProfileGuidelines and RecommendationsDosingRecommended DosageAdultsSpecial PopulationEfficacyIntra-abdominal InfectionRisk factorClinical efficacyUrinary Tract InfectionRisk factorClinical efficacyRespiratory Tract InfectionResistance rateImpactClinical efficacyFebrile NeutropeniaRisk factorTreatmentClinical efficacySafetyClinical & Scientific DataSupport & ResourcesSupport & ResourcesClinical UpdatesPrescribing InformationVideosWebinars

Indication: Monotherapy – Sulbactam/Cefoperazone is indicated for the treatment of the following infections when caused by susceptible organisms: Respiratory tract infections, urinary tract infections (upper and lower), intra-abdominal infections, septicaemia, meningitis, skin and soft tissue infections, bone and joint infections, endometritis and other infections in the genital tract. MAGNEX® FORTE is indicated for a specific subset of patients (patients with immunocompromised febrile neutropenic cancer, patients who have undergone a bone marrow transplant).1

​​​​​Clinical Efficacy

Cefoperazone/Sulbactam is recommended as an effective and a safe antibiotic for treating IAIs: Meta-analysis outcomes2

 

​​​​​​​Overall, the clinical efficacy rates of cefoperazone/sulbactam and comparators were 87.7% and 81.7%, respectively, and cefoperazone/sulbactam was associated with a higher clinical efficacy rate than its comparator (OR, 1.98; 95% CI, 1.31-3.00; I2 = 36%; P = 0.10).​​​​​​​


Adapted from Lan SH, et al. 2021.

Study Design: In this systematic review and meta-analysis, 12 studies involving 1674 patients were included. The PubMed, Cochrane, Web of Science, Ovid MEDLINE and CNKI databases were searched for relevant articles up to 25 November 2020. The primary outcome was clinical efficacy rate and the secondary outcomes were microbiologic eradication rate, mortality rate and AE risk. 

Cefoperazone/Sulbactam was associated with a higher microbiologic eradication rate than its comparator in patients with IAI: Meta-analysis outcomes2

Cefoperazone/Sulbactam was associated with a higher microbiologic eradication rate than its comparator (OR, 2.54; 95% CI, 1.72-3.76; I2 = 0).2 


Adapted from Lan SH, et al. 2021.


Higher clinical efficacy and lower clinical failure rates in IAIs as compared to the comparators2


Adapted from Lan SH, et al. 2021.

 

*Comparators included ceftizoxime, clindamycin + gentamicin, ceftriaxone, ciprofloxacin, ceftazidime/amikacin, metronidazole, ceftazidime, cefotaxime, moxifloxacin, Ievofloxacin-cefotaxime-ceftriaxone and tinidazole.
​​​​​​​
​​​​​​​AE, adverse event; CI, confidence interval; CNKI, China National Knowledge Infrastructure; df, degrees of freedom; IAI, intra-abdominal infection; OR, odds ratio.



References :

Magnex. Local product document. Pfizer; 2020. Version LPDMGX042020.​​​​​​​Lan SH, Chao CM, Chang SP, Lu LC, Lai CC. Clinical efficacy and safety of cefoperazone-sulbactam in treatment of intra-abdominal infections: a systematic review and meta-analysis. Surg Infect (Larchmt). 2021;22(8):763-770.

​​​​​​​Please click the Prescribing Information link to view the safety and adverse events information of MAGNEX®.
For the use only of registered medical practitioner, or a hospital or a laboratory.
​​​​​​​

PP-MGX-IND-0555 June 2022
Intra-abdominal Infection

About

Cefoperazone/Sulbactam: ​​​​​​​Extended coverage with β-lactamase inhibition​​​​​​

Learn more


Dosing

Recommended dosage in adult ​​​​​​and special population​​​​​​​

Learn more


Safety

Explore the safety profile of cefoperazone/sulbactam​​​​​​​

Review safety profile


Clinical & Scientific Data

Cefoperazone/Sulbactam is more efficient in the treatment ​​​​​​​of infection​​​​​​​

Learn more

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-MGX-IND-0555

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​